Artikel ; Online: The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review.
European journal of medical research
2021 Band 26, Heft 1, Seite(n) 129
Abstract: Background: It is necessary to systematically evaluate the efficacy and adverse reactions of pirfenidone in the treatment of patients with idiopathic pulmonary fibrosis (IPF).: Methods: Pubmed et al. databases were searched up to March 15, 2021 for ... ...
Abstract | Background: It is necessary to systematically evaluate the efficacy and adverse reactions of pirfenidone in the treatment of patients with idiopathic pulmonary fibrosis (IPF). Methods: Pubmed et al. databases were searched up to March 15, 2021 for randomized controlled trials (RCT) of pirfenidone in the treatment of IPF. Two authors collected and compared the indicators including progression-free survival (PFS), vital capacity (VC), forced vital capacity (FVC), and adverse reactions. RevMan 5.3 software and Stata 15.0 software were used for meta-analysis. Results: A total of 8 reports with 9 RCTs involving 1824 IPF patients were included. Meta-analysis results showed that compared with the control group, pirfenidone could prolong the PFS phase of IPF patients (HR = 0.65, 95% CI 0.55 ~ 0.76, P < 0.001), slow down the VC of IPF patients (SMD = 0.43, 95% CI 0.21 ~ 0.66, P < 0.001), and decrease FVC (SMD = 0.31, 95% CI 0.14 ~ 0.48, P < 0.001). The main adverse reactions of pirfenidone were gastrointestinal reactions, photosensitivity and skin rashes. Conclusion: Pirfenidone is beneficial to prolong the PFS of IPF patients, improve lung function, and it is safe for clinical use. However, more high-quality RCTs are still needed to provide reliable evidence for the treatment of IPF. |
---|---|
Mesh-Begriff(e) | Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Diarrhea/chemically induced ; Exanthema/chemically induced ; Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Idiopathic Pulmonary Fibrosis/physiopathology ; Lung/drug effects ; Lung/pathology ; Lung/physiopathology ; Nausea/chemically induced ; Progression-Free Survival ; Pyridones/adverse effects ; Pyridones/therapeutic use ; Treatment Outcome ; Vital Capacity/drug effects ; Vital Capacity/physiology |
Chemische Substanzen | Anti-Inflammatory Agents, Non-Steroidal ; Pyridones ; pirfenidone (D7NLD2JX7U) |
Sprache | Englisch |
Erscheinungsdatum | 2021-10-30 |
Erscheinungsland | England |
Dokumenttyp | Journal Article ; Meta-Analysis ; Systematic Review |
ZDB-ID | 1329381-3 |
ISSN | 2047-783X ; 0949-2321 |
ISSN (online) | 2047-783X |
ISSN | 0949-2321 |
DOI | 10.1186/s40001-021-00601-y |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 4636: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.